Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-12-12
2006-12-12
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07148199
ABSTRACT:
The subject invention provides dipeptides useful in preventing pathological proliferation of blood vessels. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.
REFERENCES:
patent: 4055669 (1977-10-01), Kelly et al.
patent: 4303692 (1981-12-01), Gaull
patent: 4340592 (1982-07-01), Adibi
patent: 4673578 (1987-06-01), Becker et al.
patent: 4871557 (1989-10-01), Linscott
patent: 5189016 (1993-02-01), Madsen et al.
patent: 5561111 (1996-10-01), Guerrant et al.
patent: 5576351 (1996-11-01), Yoshimura et al.
patent: 5759547 (1998-06-01), Maione
patent: 6051270 (2000-04-01), Monte
patent: 6511696 (2003-01-01), Gohman et al.
patent: 2002/0132779 (2002-09-01), Green et al.
patent: 2002/0183263 (2002-12-01), Hageman et al.
patent: 2003/0027769 (2003-02-01), Scialdone et al.
patent: 2003/0109458 (2003-06-01), Haviv et al.
patent: 2004/0138133 (2004-07-01), Cheresh et al.
patent: 2005/0070484 (2005-03-01), Neu et al.
patent: 0 182 356 (1985-09-01), None
patent: 02119762 (1990-05-01), None
patent: WO 98/09985 (1998-03-01), None
patent: WO 00/33662 (2000-06-01), None
patent: WO 01/98362 (2001-12-01), None
patent: WO 02/062371 (2002-08-01), None
patent: WO 03/017787 (2003-03-01), None
patent: WO 03/082918 (2003-10-01), None
“Diabetic Retinopathy” http://medicalcenter.osu.edu/patientcare/healthinformation/diseasesandconditions/eyecare/disorders/diabetic, accessed Aug. 18, 2005. 3 pages.
“Retinopathy of Prematurity” Kellog Eye Center U of Michigan http://www.kellogg.umich.edu/patientcare/conditions/retinopathy.prematurity.html, accessed Aug. 18, 2005. 2 pages.
“Diabetic Retinopathy. What you should know”. NIH Publication 03-2171. US Dept HHS, NIH, NEI. Revised Sep. 2003. 18 pages.
“Retinopathy of Prematurity” (Section 19, chapter 260)in The Merck Manual of Diagnosis and Therapy, 17th ed. (web version) M.H. Beers and R.A. Berkow, eds. Accessed Aug. 18, 2005 http://www.merck.com/mrkshared/mmanual/section19/chaper260/2601.jsp.
“Retinopathy of Prematurity” The Lucile Packard Children's Hospital, web document, accessed Aug. 18, 2005 http://www.lpch.org/DiseaseHealthInfo/HealthLibrary/hrnewborn.rpm.html.
English Translation for JP-02-119762, Koji et al.
Abcouwer S. et al., Response of VEGF expression to amino acid deprivation and inducers of endoplasmic reticulum street,Invest Ophthalmol Vis Sci, Aug. 2002, p. 2791-8, vol. 43, No. 8.
Adibi, S. et al., “Influence of Molecular Structure on Half-life and Hydrolysis of Dipeptides in Plasma: Importance of Glycine as N-Terminal Amino Acid Residue,”Metabolism(1986), 35(9):830-836.
Cynober, L., “Place des Nouveaux Substras Azotes en Nutrition Artificielle Perioperatoire de l'Adulte,”Ann. Fr. Anesth. Reanim.(1995), 14(Suppl. 2):102-105. (Abstract in English).
Database WPI. Derwent Publications Ltd., London GB; AN 1997-037972; XP 0021XP 002195568 & JP 08 295633 A (Otsuka Seiyaku Kogyo KK) Nov. 12, 1996, Abstract.
Le Boucher, J. et al., “Modulation of immune Response With Ornithine A-Ketoglutarate in Burn Injury: An Argine or Glutamine Dependency?”Nutrition(1999), 15(10):773-777.
Matilla B. et al., “Effects of Parenteral Nutrition Supplemented with Glutamine or Glutamine Dipeptides on Liver Antioxidant and Detoxication Systems in Rats,”Nutrition, Nutrition(2000), 16:125-128.
Mattox, T. W. et al., “Recent Advances: Parenteral Nutrition Support,”Nutrition(1995), 29(2):174-180.
Miyazawa, K. et al., “Amino-Acids and Peptide in 7 Species of Marine Green Algae,”Journal of the Faculty of Fisheries and Animal Husbandry Hiroshima(1976), 15:161-169. (Abstract from Database Biosis ‘Online’).
Moinard, C. et al., “Involvement of Glutamine, Arginine, and Polyamines in the Action of Ornithine α-Ketoglutarate on Macrophage Functions in Stressed Rats,”Journal of Leukocyte Biology(2000), 67:834-840.
Neu, J. et al., “Glutamine Nutrition and Metabolism: Where Do We Go From Here?”The FASEB Journal(1996), 10:829-837.
Robinson, L. E. et al., “Amino Acid Nutrition and Immune Function in Tumour-Bearing Rats: A Comparison of Glutamine-, Argine- and Ornithine 2-Oxoglutarate-Supplemented Diets,”Clinical Science(1999), 97:658-669.
Weckbecker, G. et al., “The Somatostatin Analog Octreotide as Potential Treatment for Re-Stenosis and Chronic Rejection,”Transplantation Proceedings(1997), 29:2599-2600.
Grant Maria B.
Neu Josef
Kosar Andrew D.
Saliwanchik Lloyd & Saliwanchik
Tsang Cecilia J.
University of Florida Research Foundation Inc.
LandOfFree
Arginyl-glutamine dipeptide for treatment of pathological... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arginyl-glutamine dipeptide for treatment of pathological..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arginyl-glutamine dipeptide for treatment of pathological... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3697769